CCT2 and neoplasm: Using CCT2 as a marker to identify circulating tumor cells in blood enhanced the ability to detect these cells from a broader range of cancers like small cell lung cancer (SCLC) that currently lack non-invasive diagnostics for patient management (Cox et al., 2022).